C0030956||Peptide
C0753209||PB2
C1505487||eIF4G1
C0872079||Interaction
C0029347||Influenza A Viruses
C0042774||Replication
C0029341||Influenza viruses
C0562628||obligate parasites
C1154502||hijack the host cellular system
C1611366||influenza virus PB2
C1505487||host eukaryotic translation initiation factor 4-Î³ 1
C1505487||eIF4G1
C1154505||viral mRNA translation
C0030956||peptide
C0753209||PB2
C1505487||eIF4G1
C0872079||interaction
C0042774||virus replication
C0001560||intranasal administration
C0030956||peptide
C3151529||lethal
C0805586||challenges
C0029347||influenza A viruses
C0025919||BALB/c mice
C1615607||H1N1
C1613950||H5N1
C3658219||H7N9 influenza virus subtypes
C0949728||Mapping
C0753209||PB2 protein
C1505487||eIF4G1
C0005456||binding sites
C0753209||PB2 cap
C1149343||binding domain
C3494274||Virtual docking analysis
C0030956||peptide
C0002520||amino acid residues
C0753209||PB2
C0201711||cap-binding activity
C0753209||PB2
C1505487||eIF4G1
C0005456||interactive site
C1254351||druggable
C0021400||influenza
C0087111||therapeutics